Deep Genomics is wasting no time. Two weeks after hiring a new chief business officer to ramp up its partnering game, it’s unveiling its first biopharma tie-up: BioMarin. The duo will use the Toronto biotech’s artificial-intelligence-based drug discovery platform to discover new drugs for rare diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,